FRC
FRC Logo
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years
Rate us on TrustpilotLeave a review

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us
  • Leave a Review

Resources

  • Videos
  • Research Reports
  • FAQ
  • How to use FRC

Browse

  • Stock Directory
  • Stock Screener
  • Market Intel Weekly
  • Report Archive

Trackers

  • Congress Trading
  • Senate Trading
  • Congress Net Worth
  • Commodities

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Research
Get Access
Sign In
SeaStar Medical Holding Corporation Stock AnalysisComprehensive stock analysis for SeaStar Medical Holding Corporation (ICU) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisICU
ICU
SeaStar Medical Holding Corporation
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
ICU
Home🔹Stocks🔹SeaStar Medical Holding Corporation

SeaStar Medical Holding Corporation

🇺🇸ICU•NASDAQ

SeaStar Medical Holding Corporation

🇺🇸ICU•NASDAQ
Market cap
$8.60M
Sentiment

Your view on ICU

Mkt Cap
$8.60M
Sentiment
Your view
ICU
SeaStar Medical Holding Corporation
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
ICU
Company Overview

Overview

What the company does, where it operates, and who runs it.

About SeaStar Medical Holding Corporation

Industry
Biotechnology
Sector
Healthcare
CEO
Eric Schlorff
Headquarters
3513 Brighton Boulevard, Denver, CO, US
Industry
Biotechnology
Sector
Healthcare
CEO
Eric Schlorff
Headquarters
3513 Brighton Boulevard, Denver, CO, US
Description

SeaStar Medical Holding Corporation, a medical device company, focuses on providing novel solutions and services to treat hyperinflammation and cytokine storm in critically ill patients.

The company is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses.

It is developing products in various therapeutic areas, including pediatric and adult acute kidney injury on CRRT; cardiorenal syndrome in congestive heart failure with and without LVAD; myocardial stunning in end stage renal disease; and hepatorenal syndrome. The company is based in Denver, Colorado.

FRC Research

Media

Infographics, videos, and posts covering the company.

Financial Data

Stock Data

Price chart, volume, and trading data.

Fair Value

What FRC thinks it is worth vs. the current price.

FRC's fair value estimate for SeaStar Medical Holding Corporation, and the rating behind it. ICU last traded at $3.03; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

Valuation, profitability, liquidity and leverage ratios for SeaStar Medical Holding Corporation. Starting points for SeaStar Medical Holding Corporation: EPS -$3.34, beta -1.03 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

Dividend history, yield and payout sustainability for SeaStar Medical Holding Corporation. SeaStar Medical Holding Corporation does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

Reported vs. expected earnings history for SeaStar Medical Holding Corporation. Trailing twelve-month EPS for SeaStar Medical Holding Corporation stands at -$3.34. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Financial Statements

Income statement, balance sheet, and cash flow statements.

Income statement, balance sheet and cash flow history for SeaStar Medical Holding Corporation. SeaStar Medical Holding Corporation has reported as a listed company since 2021. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

Peer Comparison

Comparables

List of peer companies in the same industry.

SeaStar Medical Holding Corporation valued side by side against its closest peers. SeaStar Medical Holding Corporation is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.

Ownership & News

Institutional Ownership

Premium

Which funds and firms own the stock.

Which institutions hold SeaStar Medical Holding Corporation, and how their positions are changing. At a $8.6M market value, institutional positions materially move SeaStar Medical Holding Corporation's register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.

Insider Trading

Premium

Recent buying and selling by company executives.

Buying and selling by SeaStar Medical Holding Corporation executives and directors. Shares of SeaStar Medical Holding Corporation have traded between $0.30 and $3.07 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.

Senate Trading

Premium

U.S. Senator disclosures filed under the STOCK Act.

U.S. Senate disclosures naming SeaStar Medical Holding Corporation. SeaStar Medical Holding Corporation is a $8.6M Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.

House Trading

Premium

U.S. Representative disclosures filed under the STOCK Act.

U.S. House of Representatives disclosures naming SeaStar Medical Holding Corporation. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.

News

Latest headlines and market coverage.

Latest headlines and company announcements for SeaStar Medical Holding Corporation. Coverage tracks SeaStar Medical Holding Corporation within Biotechnology (Healthcare). Press releases and market coverage, newest first.

Peer companies

  • ADTX — Aditxt, Inc.
  • AIMD — Ainos, Inc.
  • APLM — Apollomics, Inc.
  • BLRX — BioLineRx Ltd.
  • CTXR — Citius Pharmaceuticals, Inc.
  • LNAI — Lunai Bioworks Inc.

More Biotechnology companies

  • RARE — Ultragenyx Pharmaceutical Inc.
  • RASP — Actavia Life Sciences, Inc.
  • RBSH — Rebus Holdings, Inc.
  • RCAR — RenovaCare, Inc.
  • RCE.AX — Recce Pharmaceuticals Ltd
  • RCKT — Rocket Pharmaceuticals, Inc.
  • RCUS — Arcus Biosciences, Inc.
  • RDTCF — Rapid Dose Therapeutics Corp.
  • RECEF — Recce Pharmaceuticals Ltd
  • REGMF — RemeGen Co., Ltd.
  • REGN — Regeneron Pharmaceuticals, Inc.
  • REPCF — RepliCel Life Sciences Inc.

ETFs holding SeaStar Medical Holding Corporation

  • VXF — Vanguard Extended Market ETF (0.00%)
  • DFAC — Dimensional - US Core Equity 2 ETF (0.00%)

News

Latest Market News